Skip Navigation



Annals of Oncology Advance Access published online on October 9, 2006
Annals of Oncology, doi:10.1093/annonc/mdl340
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/1/82    most recent
mdl340v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wagner, A. D.
Right arrow Articles by Fleig, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagner, A. D.
Right arrow Articles by Fleig, W. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received April 24, 2006
Revised August 4, 2006
Accepted August 14, 2006

original article

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

A. D. Wagner 1 *, P. Buechner-Steudel 1, A. Wein 2, H. Schmalenberg 3, U. Lindig 3, M. Moehler 4, R. Behrens 5, G. Kleber 1, O. Kuss 6, and W. E. Fleig 1

1 First Department of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
2 First Department of Medicine, Friedrich-Alexander-University Erlangen, Erlangen, Germany
3 Department of Medicine II, Friedrich-Schiller-University, Jena, Germany
4 First Department of Medicine, Johannes-Gutenberg-University Mainz, Mainz, Germany
5 Gastroenterology Practice, Halle (Saale), Germany
6 Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

* To whom correspondence should be addressed.
A. D. Wagner, E-mail: anna-dorothea.wagner{at}gmx.de


  Abstract

Background: Combinations of gemcitabine-oxaliplatin, gemcitabine-5-fluorouracil (5-FU) and 5-FU-oxaliplatin have synergistic activity and nonoverlapping adverse effect profiles. This trial assessed efficacy and safety of the triple combination gemcitabine-oxaliplatin and infusional 5-FU in patients with locally advanced (n = 11) or metastatic (n = 32) pancreatic adenocarcinoma.

Patients and methods: A total of 43 eligible patients were treated with intravenous infusions of gemcitabine (900 mg/m2 over 30 min), followed by oxaliplatin (65 mg/m2 over 2 h) and 5-FU (1500 mg/m2 over 24 h) on days 1 and 8 of a 21-day cycle.

Results: Among all 43 patients, the tumor response rate was 19% [95% confidence interval 7% to 30%]. Nine patients were nonassessable for response because they did not complete the first two cycles of chemotherapy due to rapid disease progression, early death or treatment refusal. One patient was lost to follow-up. Median time to progression and overall survival were 5.7 and 7.5 months. Principal grade III/IV toxic effects were leucopenia in 11 (2%), thrombocytopenia in 13 (2%), nausea in 13 (0%), anorexia 16 (7%) and sensory neuropathy in 18 (0%) of patients. Unexpected cardiotoxicity was observed in this trial.

Conclusion: Response rates and survival of the three-drug combination compare favorably with single-agent gemcitabine, but do not exceed results for doublets.

Keywords: combination chemotherapy; gemcitabine; oxaliplatin; pancreatic cancer; 5-FU.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
B. R. Tan, W. S. Brenner, J. Picus, S. Marsh, F. Gao, C. Fournier, P. M. Fracasso, J. James, J. L. Yen-Revollo, and H. L. Mcleod
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
Ann. Onc., October 1, 2008; 19(10): 1742 - 1748.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.